How Will the COVID-19 Pandemic End?

E. Mostafavi
{"title":"How Will the COVID-19 Pandemic End?","authors":"E. Mostafavi","doi":"10.52547/jommid.10.3.146","DOIUrl":null,"url":null,"abstract":"More than two years after the COVID-19 pandemic outbreak, the status of the disease is still unclear to us. Up to August 1, 2022, the disease has killed about 6.4 million people worldwide, although the actual death toll is estimated to be three times more than the official death toll [1]. During this time, safe vaccines with high efficacy against the virus have been developed, methods of viral transmission and pathogenicity are better understood, and more effective treatments have been proposed that have helped better control the disease over time. A significant percentage of the world's population has acquired the infection at least once, more than 65% of the world's population has received at least one dose of a COVID-19 vaccine, and about 25% have received at least one booster dose of the COVID-19 vaccine. More than 12 billion doses have been administered globally, with 5.5 million added daily. However, the vaccine distribution is inequitable, and in low-income countries, only about 20% of people have received at least one dose of the vaccine [2]. Along with vaccines, antiviral drugs are another important achievement available. Many antiviral drugs, such as molnupiravir, fluvoxamine, and paxlovid have shown good therapeutic effects for COVID-19 patients [3].","PeriodicalId":34460,"journal":{"name":"Journal of Medical Microbiology and Infectious Diseases","volume":"39 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Microbiology and Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52547/jommid.10.3.146","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

More than two years after the COVID-19 pandemic outbreak, the status of the disease is still unclear to us. Up to August 1, 2022, the disease has killed about 6.4 million people worldwide, although the actual death toll is estimated to be three times more than the official death toll [1]. During this time, safe vaccines with high efficacy against the virus have been developed, methods of viral transmission and pathogenicity are better understood, and more effective treatments have been proposed that have helped better control the disease over time. A significant percentage of the world's population has acquired the infection at least once, more than 65% of the world's population has received at least one dose of a COVID-19 vaccine, and about 25% have received at least one booster dose of the COVID-19 vaccine. More than 12 billion doses have been administered globally, with 5.5 million added daily. However, the vaccine distribution is inequitable, and in low-income countries, only about 20% of people have received at least one dose of the vaccine [2]. Along with vaccines, antiviral drugs are another important achievement available. Many antiviral drugs, such as molnupiravir, fluvoxamine, and paxlovid have shown good therapeutic effects for COVID-19 patients [3].
COVID-19大流行将如何结束?
在2019冠状病毒病大流行爆发两年多后,我们仍然不清楚该疾病的状况。截至2022年8月1日,该疾病已导致全球约640万人死亡,尽管实际死亡人数估计是官方死亡人数的三倍[1]。在此期间,开发出了针对该病毒的安全高效疫苗,对病毒传播和致病性的方法有了更好的了解,并提出了更有效的治疗方法,帮助更好地控制该疾病。世界上相当大比例的人口至少感染过一次,超过65%的世界人口至少接种过一剂COVID-19疫苗,约25%的世界人口至少接种过一剂COVID-19疫苗加强剂。全球已注射了120多亿剂疫苗,每天增加550万剂。然而,疫苗的分配并不公平,在低收入国家,只有约20%的人接种了至少一剂疫苗[2]。除了疫苗,抗病毒药物是另一项重要成就。许多抗病毒药物,如莫诺比拉韦、氟伏沙明、paxlovid等,对COVID-19患者显示出良好的治疗效果[3]。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
16
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信